SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-164444
Filing Date
2023-06-09
Accepted
2023-06-09 16:06:52
Documents
12
Period of Report
2023-06-06
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d492050d8k.htm   iXBRL 8-K 38024
  Complete submission text file 0001193125-23-164444.txt   163175

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA agle-20230606.xsd EX-101.SCH 2844
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20230606_lab.xml EX-101.LAB 18757
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20230606_pre.xml EX-101.PRE 11706
6 EXTRACTED XBRL INSTANCE DOCUMENT d492050d8k_htm.xml XML 3472
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 231005282
SIC: 2834 Pharmaceutical Preparations